Clinical implications and management of new-onset refractory status epilepticus (NORSE)

Dr Trinka outlines key points in the management of patients with new-onset refractory status epilepticus, for improving prognosis.

Prof. Trinka has disclosed that he is/was on a speaker bureau for UCB, Eisai, Biogen, Novartis, Bial, Sunovion, Ever-Pharma, Liva-Nova, Sanofi, Hikma, Newbridge, Arvelle, GW-Pharm, Sandoz. He is/was a consultant/advisor for UCB, Eisai, Bial, Medtronic, Everpharma, GSK, Liva-Nova, Newbridge, Novartis, Sanofi, Sandoz, Biogen, Takeda, Sunovion, GW Pharm, Marinus, Arvelle, Argenix, Epilog, Clexio. He is/was a research grant recipient for Austrian Science Fund (FWF), Österreichische Nationalbank, EU, GSK, Biogen, Eisai, Novartis, Red Bull, Bayer, UCB.